Saturday 17 October 2026
Export EOLS’s income statement to Excel — free account
Evolus, Inc.
EOLS Healthcare Drug Manufacturers Specialty & Generic
Evolus, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $297.2 million, up 11.6% from fiscal 2024. In the quarter to June 2026, revenue grew 21.2%, EPS grew 55.6%, free cash flow grew 84.9% and total debt rose 7.75%, each against the same quarter a year earlier. Revenue growth for five consecutive years.
7.10
0.47
−6.21%
Follow EOLS
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
1.39 | 1.44 | 0.89 | 1.45 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(27.09) | 33.42 | (26.92) | (127.56) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
2.01 | 2.00 | 1.49 | 2.03 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(11.42) | (14.09) | (12.27) | (41.84) | |
EV/FCF |
(9.91) | (11.74) | (10.01) | (29.39) | |
Quick Ratio |
1.41 | 1.44 | 1.50 | 1.09 | |
Current Ratio |
2.02 | 1.90 | 2.04 | 1.70 | |
Net Debt/EBITDA |
(11.51) | 12.90 | (28.07) | (77.00) | |
Debt/Assets |
66.57% | 64.68% | 70.89% | 63.20% | |
Debt/Equity |
(5.07) | (6.32) | (5.43) | (5.07) | |
Asset Turnover |
1.27 | 1.30 | 1.39 | 1.33 | |
Operating CF/Net income |
0.93 | 98.67 | 0.93 | 0.45 | |
Capex/Depreciation |
(0.82) | (0.74) | (0.55) | (0.16) | |
Interest Coverage |
(2.81) | 1.06 | (1.72) | (1.09) | |
Research and Development Expense of Revenue |
2.97% | 3.85% | 3.06% | 2.25% | |
Selling, General and Administrative Expense of Revenue |
76.58% | 60.53% | 71.07% | 67.85% | |
Intangible Assets out of Total Assets |
0.32 | 0.31 | 0.31 | 0.27 | |
Share Based Compensation of Revenue |
7.45% | 5.70% | 7.00% | 6.69% | |
Graham Net Nets |
(0.28) | (0.25) | (0.41) | (0.24) | |
Graham Number |
3.03 | 2.56 | 2.58 | 2.34 | |
Earnings Yield |
(14.98%) | (12.18%) | (16.30%) | (7.49%) | |
Free Cash Flow Yield |
(14.58%) | (11.83%) | (16.75%) | (4.79%) | |
Revenue per Share |
1.07 | 1.40 | 1.12 | 1.28 | |
Operating CF per Share |
(0.23) | 0.20 | (0.15) | (0.05) | |
Capex per Share |
(0.03) | (0.03) | (0.03) | (0.01) | |
Free Cash Flow per Share |
(0.26) | 0.17 | (0.18) | (0.06) | |
Cash per Share |
0.67 | 0.83 | 0.76 | 0.69 | |
Shareholders Equity per Share |
(0.44) | (0.36) | (0.44) | (0.47) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.44) | (0.36) | (0.44) | (0.47) | |
Free Cash Flow |
(16.83) | 10.66 | (11.64) | (4.09) | |
Working Capital |
68.18 | 67.61 | 70.90 | 68.81 | |
Capital Expenditures |
(2.16) | (2.17) | (1.69) | (0.50) | |
Net Current Asset Value |
(112.87) | (106.06) | (110.50) | (111.38) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.03 | 0.02 | 0.02 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
47.54 | 51.19 | 49.84 | 55.05 | |
Average Payables |
18.40 | 16.30 | 17.85 | 33.90 | |
Average Inventory |
23.88 | 19.56 | 17.41 | 33.68 | |
Average Assets |
224.30 | 229.22 | 217.00 | 238.41 | |
Average Common Equity |
(11.43) | (8.79) | (17.69) | (24.78) |
Columns are period end dates